April 12, 2026 a 03:43 pm
MRNA: Fundamental Ratio Analysis - Moderna, Inc.
Moderna, Inc. operates in the biotechnology industry, focusing on innovative mRNA therapeutics and vaccines. The company's strong collaborations with leading pharmaceutical entities reinforce its position in the market. However, fluctuations in the biotech sector can affect its stock performance.
Fundamental Rating
Moderna, Inc. has received a moderate fundamental rating, reflecting strengths in certain areas and weaknesses in others.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 1 | |
| Return On Equity | 1 | |
| Return On Assets | 1 | |
| Debt To Equity | 1 | |
| Price To Earnings | 1 | |
| Price To Book | 4 |
Historical Rating
The historical data shows consistency in Moderna's scores over the recent period.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-04-10 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Previous | 0 | 1 | 1 | 1 | 1 | 1 | 4 |
Analyst Price Targets
The analyst estimates suggest a median price target with a consensus rating of 'Hold'.
| High | Low | Median | Consensus |
|---|---|---|---|
| $63 | $17 | $35 | $35.67 |
Responsive stock chart of Moderna, Inc.
Analyst Sentiment
The current analyst sentiment predominantly aligns towards 'Hold', with no strong buy sentiments reported.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 8 | |
| Hold | 15 | |
| Sell | 4 | |
| Strong Sell | 0 |
Conclusion
Moderna, Inc. demonstrates potential in the biotechnology space with its innovative approach to mRNA therapeutics. While the company has established substantial partnerships, its financial scores indicate areas for improvement. The 'Hold' consensus from analysts suggests cautious optimism. As with any stock, potential investors should consider both market volatility and sector dynamics. Overall, Moderna represents an interesting opportunity for those seeking exposure to biotechnology.